Compound that enhances ferroptosis of cancer cells is identified
February 9, 2022
A new inhibitor against ferroptosis suppressing protein FSP1
An international cooperative research group of RIKEN CSRS and Max Plank Institute of Molecular Physiology identified a new compound that enhances regulated cell death called “ferroptosis”.
Ferroptosis is associated with various diseases including cancer. As some types of cancer resistant to existing anti-cancer drugs have high susceptibility to ferroptosis, induction of ferroptosis has been expected as a new therapeutic strategy against cancer.
The international cooperative group identified a small molecule compound NPD4928 by screening the RIKEN NPDepo chemical library for potential inhibitors of cancer cell growth. The analysis of its action revealed that NPD4928 inhibits functions of FSP1, a ferroptosis suppressor protein.
This study results are expected to contribute to understanding molecular mechanisms of ferroptosis and developing therapies for diseases such as drug-resistant cancer.
- Original article
- ACS Chemical Biology doi:10.1021/acschembio.2c00028
- H. Yoshioka, T. Kawamura, M. Muroi, Y. Kondoh, K. Honda, M. Kawatani, H. Aono, H. Waldmann, N. Watanabe, H. Osada,
- "Identification of a Small Molecule That Enhances Ferroptosis via Inhibition of Ferroptosis Suppressor Protein 1 (FSP1)".
- Hiromasa Yoshioka; Postdoctoral Researcher
- Makoto Muroi; Senior Research Scientist
- Hiroyuki Osada; Group Director
- Chemical Biology Research Group